SOD1 mRNA
Nucleic acid in Homo sapiens that 1 drug acts on.
- Drugs that act on it: 1
- Approved: 1
- In phases 1 to 3: 0
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on this target, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Other 1
| Tofersen in Non-SOD1 ALS | Tofersen | Phase 2 | Recruiting | Washington University School of Medicine | Dec 19, 2025 |
| A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD-1) Amyotrophic Lateral Sclerosis (ALS) | Tofersen | — | Recruiting | Biogen | Dec 2, 2025 |
| A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS) | Tofersen | Phase 4 | Active, not recruiting | Biogen | Nov 3, 2025 |
| Rehabilitation and Exercise in SOD1-ALS TOfersen REcipients (RESTORE) | Tofersen | — | Enrolling by invitation | Washington University School of Medicine | Feb 13, 2023 |
| Study to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms | Tofersen | Phase 3 | Active, not recruiting | Biogen | Apr 23, 2021 |
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3833461, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets